Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
21/01/2026 19:10
Jan 21 (Reuters) - AB Science SA ABS.PA: AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 Source text: ID:nGNX45KYJb Further company coverage: ABS.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease